Literature DB >> 3481313

Ofloxacin treatment in the management of chronic osteitis.

R Ketterl1, T Beckurts, B Stübinger, B Claudi.   

Abstract

In an open prospective study, the efficacy and tolerability of ofloxacin in the treatment of chronic post-traumatic osteitis was examined in 83 patients. 103 different pathogens were isolated. More than 75% were Gram-positive bacteria with Staphylococcus aureus occurring in 61% of cases. After ofloxacin treatment bacteriological elimination was more than 90% for both Gram-positive and Gram-negative species, leading to a clinical cure in 85% of patients. Reinfection occurred in 5% of patients. These values were obtained from follow-up examinations which were carried out at least 6 months after the end of therapy. The tolerability of ofloxacin was excellent and no drug-related allergic reactions or side effects were observed. In conjunction with adequate surgical treatment, ofloxacin proved to be a useful antibacterial agent in the therapy of chronic bone infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481313     DOI: 10.2165/00003495-198700341-00027

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  8 in total

1.  [Incidence of osteomyelitis after osteosynthesis].

Authors:  J Probst
Journal:  Chirurg       Date:  1977-01       Impact factor: 0.955

Review 2.  Review of bacterial resistance--a challenge to the treatment of urinary infection.

Authors:  R Slack
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

3.  [Treatment of chronic bone infections with extensive skin/soft tissue defect using free transplanted flaps with microvascular anastomoses].

Authors:  H G Schmidt; B D Partecke
Journal:  Unfallheilkunde       Date:  1984-10

4.  [Use of PMMA gentamicin bead chains following early infection without the removal of osteosynthesis material].

Authors:  V Vécsei; W Scharf; H Tomiczek
Journal:  Unfallheilkunde       Date:  1983-01

5.  [Immunology and bacteriology of post-traumatic bone infections].

Authors:  M Eibl; R Passl
Journal:  Hefte Unfallheilkd       Date:  1982

6.  In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.

Authors:  S Nakamura; A Minami; H Katae; S Inoue; J Yamagishi; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

7.  In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.